CLINICAL_TRIALS
trial_result
· 2021-02-10
Clinical Trial Update: Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma [Phase 2]
Summary
Phase 2 trial of adjuvant intraperitoneal gemcitabine for resectable pancreatic adenocarcinoma was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Medstar Health Research Institute | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-02-10